Compugen (NASDAQ:CGEN) will be issuing its n/a quarterly earnings data before the market opens on Wednesday, February 21st.
Shares of Compugen (CGEN) opened at $2.90 on Wednesday. Compugen has a 1 year low of $2.25 and a 1 year high of $5.40. The firm has a market cap of $138.06, a price-to-earnings ratio of -4.08 and a beta of 0.68.
CGEN has been the topic of several research reports. Zacks Investment Research upgraded shares of Compugen from a “hold” rating to a “buy” rating and set a $3.75 price target on the stock in a research report on Friday, January 19th. ValuEngine cut shares of Compugen from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.